ArticleCancer imaging : the official publication of the International Cancer Imaging Society2026
Efficacy of targeted chemokine receptor 4 PET/CT in evaluating active lesions in multiple myeloma, comparison to
Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundTo compare the performance between chemokine receptor 4 (CXCR4) targeting PET/CT and 18F-Fluorodeoxyglucose (FDG) PET/CT in detecting active tumors in newly diagnosed (ND) and post-treated (PT)multiple myeloma (MM) patients.
methods53 MM patients were recruited, comprising 10 NDMM and 43 PTMM. All patients underwent 68Ga-Pentixafor PET/CT, and 30 patients additionally received 18F-FDG PET/CT within one week. A positive focal lesion for visual analysis was defined as a lesion with a diameter greater than 5 mm, exhibiting uptake exceeding that of the surrounding normal bone tissue. Diffuse bone marrow uptake was characterized as homogeneous bone marrow uptake that was higher than liver. The number of lesions was recorded according to nine skeletal regions plus extramedullary sites. The maximum standard uptake values (SUVmax) and target to background ratios (TBR) of the most significant lesions in each region were calculated for semi-quantitative analysis. All patients provided samples from bone marrow or extramedullary tissues, with biopsy results confirming plasmacytoma or plasma cell analysis identifying monoclonal plasma cells ≥ 10% serving as the gold standard for the presence of active tumors.
results68Ga-Pentixafor demonstrated a higher sensitivity than 18F-FDG in the overall sample (95.8% vs. 81.3%), NDMM (90% vs. 77.8%) and PTMM (100% vs. 85.7%). In head-to-head comparisons, 68Ga-Pentixafor detected more lesions than 18F-FDG in all regions. The SUVmax and TBR of 68Ga-Pentixafor were significantly higher than those of 18F-FDG (p < 0.001). In 68Ga-Pentixafor, the lesions in NDMM exhibited significantly lower SUVmax and TBR compared to those in PTMM (p < 0.05). There was no significant difference in FDG uptake between NDMM and PTMM lesions.
conclusion68Ga-Pentixafor demonstrates superior performance in detecting active lesions in both newly diagnosed and post-treated MM patients than 18F-FDG. CXCR4-targeted PET/CT may serve as a promising tool for diagnosing and monitoring treatment response of MM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.